Literature DB >> 8747932

Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay.

B Stausbøl-Grøn1, O S Nielsen, S Møller Bentzen, J Overgaard.   

Abstract

The assumed selective growth of tumour cells has formed the basis for the use of the soft agar clonogenic assay to test in vitro radio- and chemosensitivity of tumours. However, recent studies have demonstrated that fibroblasts proliferate in soft agar in addition to tumour cells. The present study was initiated to quantify the contaminating growth of non-malignant cells in the modified form of the Courtenay-Mills soft agar assay, in order to establish a reliable assay for estimating tumour cell radiosensitivity in squamous cell carcinomas of the head and neck. DNA flow cytometry analysis confirmed that 'tumour fibroblasts' (fibroblasts obtained from tumour biopsies) grow in soft agar. In contrast, white blood cells did not form colonies. Different media were tested with soft agar, but a selective medium for tumour cells was not found. Therefore, a colony filter-technique combined with an immunocytochemical analysis was developed to quantify the number of tumour cell and fibroblast colonies. In 12 tumour biopsies, 2-33% of the colonies were Cytokeratin AE1-3 positive, whereas 83-100% of the colonies were 5B5 fibroblast antibody positive. The parameter normally reported, the overall SF2 (surviving cell fraction at 2 Gy) based on colonies in agar, was found to be statistically significantly correlated to the fibroblast SF2, but not to the tumour cell SF2. The overall SF2 was significantly different from the tumour cell SF2 in half of the tumours. Furthermore, the tumour cell SF2 was not correlated to fibroblast SF2. In consequence of our findings, correcting for fibroblast contamination is a necessity, when studying in vitro sensitivity of tumour cells. Combining the soft agar clonogenic assay with the new colony filter-technique and the immunocytochemical analysis appear to be useful for making this routine correction and for measuring the in vitro radiosensitivity of both tumour cells and fibroblasts from single tumour biopsies, which is of interest in future clinical studies on predictive assays.

Entities:  

Mesh:

Year:  1995        PMID: 8747932     DOI: 10.1016/0167-8140(95)98589-d

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

2.  The in vitro radiosensitivity of human head and neck cancers.

Authors:  T Björk-Eriksson; C M West; E Karlsson; N J Slevin; S E Davidson; R D James; C Mercke
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

3.  The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix.

Authors:  C M West; S E Davidson; S A Roberts; R D Hunter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Authors:  Amy J C Dohmen; Justin E Swartz; Michiel W M Van Den Brekel; Stefan M Willems; René Spijker; Jacques Neefjes; Charlotte L Zuur
Journal:  Cancers (Basel)       Date:  2015-08-28       Impact factor: 6.639

5.  Sponge-supported cultures of primary head and neck tumors for an optimized preclinical model.

Authors:  Amy J C Dohmen; Joyce Sanders; Sander Canisius; Ekaterina S Jordanova; Else A Aalbersberg; Michiel W M van den Brekel; Jacques Neefjes; Charlotte L Zuur
Journal:  Oncotarget       Date:  2018-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.